Chemical Component Summary

NameTicagrelor
Identifiers(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-[3,4-bis(fluoranyl)phenyl]cyclopropyl]amino]-5-propylsulfanyl-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethyloxy)cyclopentane-1,2-diol
FormulaC23 H28 F2 N6 O4 S
Molecular Weight522.57
TypeNON-POLYMER
Isomeric SMILESCCCSc1nc(c2c(n1)n(nn2)[C@@H]3C[C@@H]([C@H]([C@H]3O)O)OCCO)N[C@@H]4C[C@H]4c5ccc(c(c5)F)F
InChIInChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1
InChIKeyOEKWJQXRCDYSHL-FNOIDJSQSA-N

Chemical Details

Formal Charge0
Atom Count64
Chiral Atom Count6
Bond Count68
Aromatic Bond Count16

Drug Info: DrugBank

DrugBank IDDB08816 
NameTicagrelor
Groupsapproved
DescriptionTicagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism.[A2903] Unlike [clopidogrel], ticagrelor is not a prodrug.[A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010.[L14207] Ticagrelor was granted FDA approval on 20 July 2011.[L14201]
Synonyms
  • (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
  • Ticagrelor
Brand Names
  • Apo-ticagrelor
  • Taro-ticagrelor
  • Brilique
  • Ticagrelor
  • Na
IndicationTicagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction.[L14201] Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.[L14201]
Categories
  • Anticoagulants
  • Antiplatelet agents
  • Blood and Blood Forming Organs
  • Carbohydrates
  • Cytochrome P-450 CYP2B6 Inducers
ATC-CodeB01AC24
CAS number274693-27-5

Drug Targets

NameTarget SequencePharmacological ActionActions
P2Y purinoceptor 12MQAVDNLTSAPGNTSLCTRDYKITQVLFPLLYTVLFFVGLITNGLAMRIF...unknowninhibitor
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate,inhibitor
Cytochrome P450 3A5MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNV...unknownsubstrate,activator
Cytochrome P450 2B6MELSVLLFLALLTGLLLLLVQRHPNTHDRLPPGPRPLPLLGNLLQMDRRG...unknowninducer
Cytochrome P450 2C9MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI...unknowninhibitor,inducer
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
CCDC/CSDJEMWOQ
PubChem9871419
ChEBICHEBI:68558
ChEMBLCHEMBL398435
PharosCHEMBL398435